Takeda plans Japan drug filing next year
Takeda Pharmaceutical will seek Japanese regulatory approval next year for its gastric cancer drug after a late stage study showed it significantly extended overall survival and delayed disease progression in advanced patients.
Xurve View
Insights:
Xurve View
Takeda Pharmaceutical Co Ltd will file a new drug application in Japan next year for its gastric cancer drug after a late-stage trial met main survival goals. The treatment extended median overall survival to 10.2 months compared with 6.9 months for standard chemotherapy. The filing marks a key test for the drugmaker's refined oncology strategy in core tumor targets.
